Filter posts

New York Legislators to PTO Head: Stop IPR Abuse

This week ten members the U.S. House of Representatives from New York wrote to U.S. …

BIO's Statement Regarding SCOTUS Patent Review Decision

BIO issued the following statement following yesterday’s Supreme Court decision in the case of Cuozzo …

"II Ca-Be-lly, or Not II Ca-Be-lly?”: Is The Famous Cabilly II Antibody Patent Near Extinction?

Guest post by Konstantin Linnik, Ph.D., Isaac Hubner, Ph.D, and Lana Gladstein, who are attorneys …

#BIOCEO16 Fireside Chat with Senator Chuck Schumer

New York Senator Chuck Schumer joined attendees at the 2016 BIO CEO & Investor Conference …

Patent Reform in the News

The New York Post and The Washington Post have both run Op-eds in the last week addressing …

Biotech Policy Outlook at #BIF15: 21st Century Cures, IPR, TPP, and PDUFA VI

To even the most casual observer, 2015 has been a big year in the biotech …

PTAB Ruling Proves Medical Innovation Under Attack

There’s more evidence today that the IPR system needs to be fixed. PTAB ruled on …

BIO on CNBC: IPR System Weakens Medical Innovation

Last night Ron Cohen, M.D., CEO of Acorda Therapeutics and BIO’s board chair, appeared on …

Here are the Facts about the IPR Kill Rate

FiercePhrma recently ran an article repeating a dubious analysis of the crisis caused by the …

102 Organizations Urge Congress to Maintain a Strong Patent System and Protect Innovation

A diverse group of more than 100 national and state-based advocacy organizations have united to …